Quest Diagnostics Launches New AD-Detect™ Blood Test To Aid In Confirming Alzheimer’s Disease

Quest Diagnostics began offering a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in people with mild cognitive impairment (MCI) or dementia. The laboratory-developed test, named AD-Detect™ Abeta 42/40 and p-tau217 Evaluation, builds on prior AD-Detect tests.

The new test combines results of blood levels of amyloid beta (AB) 42/40 determined by the company's proprietary tandem mass spectrometry techniques with blood levels of p-tau217. The test results are used to produce the AD-Detect Likelihood Score™, a composite interpretation created through a . . .